CARA shareholders approve doubling authorized shares and authorize reverse stock split

Tvardi Therapeutics, Inc.

Authorized common stock increased from 100M to 200M shares; 76.5% of votes in favor.
Board authorized to implement reverse stock split at ratio 1:4 to 1:12, with proportionate reduction in authorized shares.
Directors Susan Shiff and Helen Boudreau elected; advisory say-on-pay passed with 16.3M for vs 10.7M against.
Ernst & Young ratified as independent auditor for FY2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.